Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2022.4556
Abstract: Importance Combination immunotherapy with nivolumab and ipilimumab has markedly improved outcomes for patients with advanced melanoma. However, these therapies pose a considerable financial burden to both patients and the health care system. The ADAPT-IT trial… read more here.
Keywords: advanced melanoma; cost; response adapted; response ... See more keywords
Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.0165
Abstract: Key Points Question Is a response-adapted strategy based on early tumor response to radiotherapy associated with improved survival with a functional larynx in patients with resectable locally advanced hypopharyngeal carcinoma? Findings In this cohort study… read more here.
Keywords: locally advanced; radiotherapy; response adapted; patients resectable ... See more keywords
Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2555
Abstract: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. read more here.
Keywords: adapted treatment; response adapted; treatment rituximab; rituximab bendamustine ... See more keywords
Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features.
Sign Up to like & getrecommendations! Published in 2021 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2021.100788
Abstract: Lenalidomide and low-dose dexamethasone (Rd) are a standard treatment for older adults with multiple myeloma (MM). Lenalidomide monotherapy has rarely been evaluated for newly diagnosed transplant-ineligible MM patients. This multicenter phase II trial evaluated a… read more here.
Keywords: response adapted; ineligible patients; transplant ineligible; newly diagnosed ... See more keywords